Dexycu Kit is a drug owned by Eyepoint Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2018 to 2022. Out of these, 5 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 23, 2039. Details of Dexycu Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11097061 | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(14 years from now) | Active |
| US10022502 | Dose guides for injection syringe |
Jun, 2034
(9 years from now) | Active |
| US10159683 | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(9 years from now) | Active |
| US10028965 | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(9 years from now) | Active |
| US10799642 | Dose guides for injection syringe |
May, 2032
(7 years from now) | Active |
| US6960346 | Vehicles for delivery of biologically active substances |
Jul, 2023
(1 year, 4 months ago) |
Expired
|
| US7560120 | Vehicles for delivery of biologically active substances |
Sep, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dexycu Kit's patents.
Latest Legal Activities on Dexycu Kit's Patents
Given below is the list of recent legal activities going on the following patents of Dexycu Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Mar, 2024 | US10799642 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Jun, 2022 | US10159683 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Jan, 2022 | US10028965 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 05 Jan, 2022 | US10022502 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Aug, 2021 | US11097061 |
| Recordation of Patent Grant Mailed Critical | 24 Aug, 2021 | US11097061 |
| Email Notification Critical | 05 Aug, 2021 | US11097061 |
| Issue Notification Mailed Critical | 04 Aug, 2021 | US11097061 |
| Dispatch to FDC | 22 Jul, 2021 | US11097061 |
| Application Is Considered Ready for Issue Critical | 22 Jul, 2021 | US11097061 |
FDA has granted several exclusivities to Dexycu Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Dexycu Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Dexycu Kit.
Exclusivity Information
Dexycu Kit holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Dexycu Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2021 |
US patents provide insights into the exclusivity only within the United States, but Dexycu Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dexycu Kit's family patents as well as insights into ongoing legal events on those patents.
Dexycu Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dexycu Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 23, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dexycu Kit Generic API suppliers:
Dexamethasone is the generic name for the brand Dexycu Kit. 30 different companies have already filed for the generic of Dexycu Kit, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dexycu Kit's generic
Alternative Brands for Dexycu Kit
Dexycu Kit which is used for reducing postoperative inflammation., has several other brand drugs using the same active ingredient (Dexamethasone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
| |
| Dexcel |
| |
| Harrow Eye |
| |
| Ocular Therapeutix |
| |
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dexamethasone, Dexycu Kit's active ingredient. Check the complete list of approved generic manufacturers for Dexycu Kit
About Dexycu Kit
Dexycu Kit is a drug owned by Eyepoint Pharmaceuticals Inc. It is used for reducing postoperative inflammation. Dexycu Kit uses Dexamethasone as an active ingredient. Dexycu Kit was launched by Eyepoint Pharms in 2018.
Approval Date:
Dexycu Kit was approved by FDA for market use on 09 February, 2018.
Active Ingredient:
Dexycu Kit uses Dexamethasone as the active ingredient. Check out other Drugs and Companies using Dexamethasone ingredient
Treatment:
Dexycu Kit is used for reducing postoperative inflammation.
Dosage:
Dexycu Kit is available in suspension form for intraocular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 9% | SUSPENSION | Prescription | INTRAOCULAR |